Vericel (VCEL) Free Cash Flow Growth (3y) (2013 - 2026)
Vericel (VCEL) Free Cash Flow Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,440.76 Bn | 66,440.47 Bn | - | -5.05% |
| 2 | Nanobiotix | 1,909.20 Bn | 1,909.14 Bn | - | - |
| 3 | Akari Therapeutics | 1,009.43 Bn | 1,009.43 Bn | - | - |
| 4 | BeOne Medicines | 468.28 Bn | 463.49 Bn | 1.35 Bn | 31.07% |
| 5 | Vertex Pharmaceuticals | 122.49 Bn | 115.24 Bn | 2.59 Bn | 14.71% |
| 6 | Regeneron Pharmaceuticals | 70.26 Bn | 61.51 Bn | 3.31 Bn | -10.65% |
| 7 | Belite Bio | 62.88 Bn | 62.88 Bn | - | - |
| 8 | Argenx Se | 55.67 Bn | 50.48 Bn | 1.41 Bn | - |
| 9 | Alnylam Pharmaceuticals | 37.37 Bn | 34.36 Bn | 959.66 Mn | 31.42% |
| 10 | Vericel | 2.30 Bn | 2.15 Bn | 49.27 Mn | 32.88% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 32.88% |
| Dec 31, 2025 | -210.82% |
| Sep 30, 2025 | 112.88% |
| Jun 30, 2025 | -75.27% |
| Mar 31, 2025 | -178.79% |
| Dec 31, 2024 | 55.49% |
| Sep 30, 2024 | -114.56% |
| Jun 30, 2024 | -29.12% |
| Mar 31, 2024 | -35.98% |
| Dec 31, 2023 | -18.77% |
| Sep 30, 2023 | 12.13% |
| Jun 30, 2023 | 59.90% |
| Mar 31, 2023 | 17.55% |
| Dec 31, 2022 | -27.46% |
| Sep 30, 2022 | -13.19% |
| Jun 30, 2022 | 31.55% |
| Mar 31, 2022 | 90.94% |
| Dec 31, 2021 | 99.30% |
| Sep 30, 2021 | 9.54% |
| Jun 30, 2021 | 28.75% |